Results of Validcare Study of 839 Adults Ingesting CBD Report No Liver Toxicity
"We support using clinical science to inform our nation's health regulators, lawmakers, state and federal regulators but most importantly, we believe in using clinical science to build longterm consumer trust," said
The FDA requested very specific liver toxicity data last March in its letter to
The study's methodology used a decentralized, observational approach with adult consumers of full and broad spectrum hemp extracts and CBD isolates. The Company provided Charlotte's Web™ full-spectrum hemp extract products to its recruited participants. Each participating CBD company recruited a cohort of participants who are already CBD users and who have been prior users of CBD for a minimum of 30 days to meet study inclusion criteria. The study called for a minimum of 681 participants to achieve statistical relevance; the study netted at 839 participants who agreed to requirements of the study including blood lab work.
"Charlotte's Web was among the first companies to step up and commit to support for this liver safety study," said
"The findings validate our view. Charlotte's Web is committed to safety studies to support regulators and confident consumer access to hemp-derived dietary supplements like Charlotte's Web products," said Tim Orr, Senior Vice President of Charlotte's Web and President of its
About
Founded in 2013 by the pioneering
Subscribe to Charlotte's Web investor news.
Forward-Looking Information
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Charlotte's Web to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including assumptions as to the efficacy and results of research; the adverse impact of the COVID-19 pandemic to the Company's operations; and such risks contained in Charlotte's Web's annual information form dated
View original content to download multimedia:http://www.prnewswire.com/news-releases/charlottes-web-advances-cbd-science-through-landmark-liver-safety-study-301253949.html
SOURCE
© Canada Newswire, source